Table 1.

APHINITY demographics

Demographic parametersChemotherapy, trastuzumab and pertuzumab N = 2,400, n (%)Chemotherapy, trastuzumab and placebo N = 2,404, n (%)
Sex
 Male3 (0.1)8 (0.3)
 Female2,397 (99.9)2,396 (99.7)
Age
 Mean years (SD)51.7 (10.9)51.4 (10.7)
 Median (years)5151
 Min, max (years)22, 8618, 85
Age group
 <65 years2,085 (86.9)2,111 (87.8)
 ≥65 years315 (13.1)293 (12.2)
 ≥75 years30 (1.3)26 (1.1)
Race
 White1,705 (71.0)1,694 (70.5)
 Black or African American32 (1.3)41 (1.7)
 Asian590 (24.6)598 (24.9)
 American Indian or Alaska Native57 (2.4)56 (2.3)
 Native Hawaiian or other Pacific Islander3 (0.1)7 (0.3)
 Othera13 (0.5)8 (0.3)
Ethnicity
 Hispanic or Latino45 (1.9)42 (1.7)
 Not Hispanic or Latino432 (18.0)386 (16.1)
 Not reported/unknown1,923 (80.1)1,976 (82.2)
Region
 United States296 (12.3)294 (12.2)
 Rest of the world2,104 (87.7)2,110 (87.8)
 Canada64 (2.7)46 (1.9)
 Central and South America60 (2.5)64 (2.7)
 Europe1,345 (56.0)1,340 (55.7)
 Asia573 (23.9)573 (23.8)
 Australia/New Zealand53 (2.2)75 (3.1)
 Africa (South Africa)9 (0.4)12 (0.5)
  • aData on ethnicity were collected primarily at U.S. sites.